

Please amend claim 1 as follows:

- sub E2
D2
1. (Twice amended) A method for [treating L-selectin mediated inflammation] inhibiting the binding of a native L-selectin to peripheral lymphoid tissue comprising [administering to a patient in need a therapeutically effective amount of
- a)] contacting said L-selectin with an isolated, purified CD34 glycoprotein having the [endothelial] glycoform of native CD34 isolated from peripheral lymph nodes.

Please add the following claim:

- D2
- 28. The method of claim 1 wherein said CD34 is isolated and purified from peripheral lymph nodes.--

Support for the Amendments

The amendments in claim 1 are supported at least at page 1, lines 39-45; page 3, lines 1-18; and Example 1. Since the amendments do not require new search or extensive consideration by the Examiner, rather are believed to bring the claims in a form ready for allowance or, at least, reduce the issues for appeal, their entry after final rejection is respectfully requested.

The Rejections

1. Applicants were requested to update the status of the parent application on the first line of the specification, which was done in the foregoing amendment.